{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:02:05Z","timestamp":1785250925895,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["T1078-B"],"award-info":[{"award-number":["T1078-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["KLI 978"],"award-info":[{"award-number":["KLI 978"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["I 5123-B"],"award-info":[{"award-number":["I 5123-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011597","name":"Penn State Hershey Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011597","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128729","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:01:03Z","timestamp":1779148863000},"page":"128729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A chimeric L1-L2 virus-like particle (VLP) vaccine targeting common cutaneous human papillomavirus type 1 (HPV1)"],"prefix":"10.1016","volume":"86","author":[{"given":"Huber","family":"Bettina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanchez Jimenez","family":"Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirnbauer","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2026.128729_bb0005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","author":"Bernard","year":"2010","journal-title":"Virology"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128729_bb0010","doi-asserted-by":"crossref","first-page":"11636","DOI":"10.1128\/JVI.74.24.11636-11641.2000","article-title":"The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses","volume":"74","author":"Antonsson","year":"2000","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128729_bb0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/cup.70002","article-title":"Skin tumors associated with cutaneous HPV infection","volume":"53","author":"Sullivan","year":"2026","journal-title":"J Cutan Pathol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128729_bb0020","doi-asserted-by":"crossref","first-page":"700","DOI":"10.5858\/arpa.2017-0572-RA","article-title":"Human papillomavirus infection of the skin","volume":"142","author":"Bacaj","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128729_bb0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11904-009-0018-8","article-title":"Dermatologic manifestations of HPV in HIV-infected individuals","volume":"6","author":"Gormley","year":"2009","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128729_bb0030","first-page":"165","article-title":"Different skin wart types, different human papillomavirus types? A narrative review","volume":"32","author":"Skubic","year":"2023","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128729_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175892","article-title":"Molecular characterization, tissue tropism, and genetic variability of the novel Mupapillomavirus type HPV204 and phylogenetically related types HPV1 and HPV63","volume":"12","author":"Sterbenc","year":"2017","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128729_bb0040","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/bjd.15751","article-title":"The EVerT2 (effective Verruca treatments 2) trial: a randomized controlled trial of needling vs. nonsurgical debridement for the treatment of plantar verrucae","volume":"177","author":"Hashmi","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128729_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2025.103406","article-title":"A multicentre pragmatic randomized controlled trial comparing 50% salicylic acid, liquid nitrogen, 5% 5-fluorouracil cream, and 5% imiquimod cream in previously treated plantar warts. The VRAIE (VeRrues plAntaIres en villE) study","volume":"152","author":"Chanal","year":"2025","journal-title":"Ann Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128729_bb0050","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcv.2012.07.014","article-title":"Cutaneous wart-associated HPV types: prevalence and relation with patient characteristics","volume":"55","author":"Bruggink","year":"2012","journal-title":"J Clin Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128729_bb0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s004030050201","article-title":"Clinical features and age distribution of patients with HPV 2\/27\/57-induced common warts","volume":"289","author":"Rubben","year":"1997","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128729_bb0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jmv.20421","article-title":"A genotype distribution of human papillomaviruses detected by polymerase chain reaction and direct sequencing analysis in a large sample of common warts in Japan","volume":"77","author":"Hagiwara","year":"2005","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128729_bb0065","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4161\/hv.27925","article-title":"Comparison of the immunogenicity of Cervarix(R) and Gardasil(R) human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults","volume":"10","author":"Toft","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"48","key":"10.1016\/j.vaccine.2026.128729_bb0070","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1016\/j.vaccine.2013.09.032","article-title":"Safety and immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study","volume":"31","author":"Denny","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128729_bb0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","article-title":"Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination","volume":"41","author":"Joshi","year":"2023","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128729_bb0080","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128729_bb0085","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00566-22","article-title":"RG2-VLP: a vaccine designed to broadly protect against anogenital and skin human papillomaviruses causing human cancer","volume":"96","author":"Olczak","year":"2022","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128729_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-42678-7","article-title":"Assessment of mycobacterium tuberculosis dodecin scaffold as a multimerization platform on the immunogenicity of HPV L2 antigens","volume":"16","author":"Kaplan","year":"2026","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128729_bb0095","article-title":"Vaccination with a human papillomavirus L2 Multimer provides broad protection against 17 human papillomavirus types in the mouse Cervicovaginal challenge model","volume":"12","author":"Han","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2026.128729_bb0100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2013.04.017","article-title":"L2, the minor capsid protein of papillomavirus","volume":"445","author":"Wang","year":"2013","journal-title":"Virology"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128729_bb0105","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"A protective and broadly cross-neutralizing epitope of human papillomavirus L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128729_bb0110","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.virol.2006.08.037","article-title":"Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region","volume":"358","author":"Kondo","year":"2007","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128729_bb0115","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.73.7.6188-6190.1999","article-title":"Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6","volume":"73","author":"Kawana","year":"1999","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128729_bb0120","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1038\/jid.2013.253","article-title":"Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses","volume":"133","author":"Schellenbacher","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128729_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169533","article-title":"Chimeric L2-based virus-like particle (VLP) vaccines targeting cutaneous human papillomaviruses (HPV)","volume":"12","author":"Huber","year":"2017","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128729_bb0130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/bjd.13216","article-title":"High prevalence of cutaneous warts in elementary school children and the ubiquitous presence of wart-associated human papillomavirus on clinically normal skin","volume":"172","author":"de Koning","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128729_bb0135","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1128\/JVI.78.2.751-757.2004","article-title":"Efficient intracellular assembly of papillomaviral vectors","volume":"78","author":"Buck","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128729_bb0140","series-title":"Curr Protoc Cell Biol","article-title":"Production of papillomavirus-based gene transfer vectors","author":"Buck","year":"2007"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128729_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120152","article-title":"A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types","volume":"10","author":"Huber","year":"2015","journal-title":"PloS One"},{"issue":"19","key":"10.1016\/j.vaccine.2026.128729_bb0150","doi-asserted-by":"crossref","first-page":"10085","DOI":"10.1128\/JVI.01088-09","article-title":"Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines","volume":"83","author":"Schellenbacher","year":"2009","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128729_bb0155","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41541-022-00539-0","article-title":"A broadly protective vaccine against cutaneous human papillomaviruses","volume":"7","author":"Mariz","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128729_bb0160","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/CVI.00139-12","article-title":"A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies","volume":"19","author":"Day","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"21","key":"10.1016\/j.vaccine.2026.128729_bb0165","first-page":"7515","article-title":"The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors","volume":"63","author":"Iftner","year":"2003","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128729_bb0170","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"Roberts","year":"2007","journal-title":"Nat Med"},{"issue":"34","key":"10.1016\/j.vaccine.2026.128729_bb0175","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.vaccine.2014.06.054","article-title":"Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing","volume":"32","author":"Tyler","year":"2014","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2026.128729_bb0180","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1016\/j.vaccine.2015.05.016","article-title":"Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2","volume":"33","author":"Tumban","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128729_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1010790","article-title":"Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development","volume":"13","author":"Ahmels","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128729_bb0195","first-page":"e37","volume":"1","author":"Laar","year":"2025","journal-title":"Lancet Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128729_bb0200","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1128\/JCM.41.6.2509-2514.2003","article-title":"General acquisition of human papillomavirus infections of skin occurs in early infancy","volume":"41","author":"Antonsson","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128729_bb0205","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/JVI.01338-08","article-title":"Intrafamilial transmission and family-specific spectra of cutaneous betapapillomaviruses","volume":"83","author":"Weissenborn","year":"2009","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:40:37Z","timestamp":1785249637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"alternative-id":["S0264410X26005384"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128729","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A chimeric L1-L2 virus-like particle (VLP) vaccine targeting common cutaneous human papillomavirus type 1 (HPV1)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128729"}}